Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameHenlius
Stock Code02696
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家中國領先的生物製藥公司,旨在為全球患者提供質高價優的創新藥物。主要專注研發單克隆抗體藥物並提供相關技術服務,已商業化推出生物類似藥產品HLX01(漢利康),並自主開發20種以上候選生物藥及多種腫瘤免疫聯合療法。
Listing Date2019-09-25
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市徐匯區虹梅路1801號凱科國際大廈A座9樓
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.henlius.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 49.60 / shares
Offer Price RangeTo be extracted
Lot Size100 shares
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2019-09-12 to 2019-09-17
Global Offering Shares64,695,400 shares
HK Public Offer Shares (Initial)6,469,600 shares (10.0%)
Public Offer Lots (Initial)64,696lots (Pool A32,348lots,Pool B32,348lots)
International Placing Shares (Initial)58,225,800 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO539,128,704 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share34.2%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 3,208,891,840

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
3,020 lots 302,048 HK$ 14,981,581
4,704 lots 470,404 HK$ 23,332,038

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 21.29B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损约人民币504.8百万元
Period-End Cash Balance人民币959.0百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO Investment约人民币43亿元

Financial Data

Unit: '000 RMB
Income Statement
Item 201720182019-03
Revenue 33,9107,421924
Cost of sales -15,019-5,398
Gross profit 18,8912,023924
Other income and gains, net 1,16530,3084,830
Selling and distribution expenses -5,082
Administrative expenses -87,334-109,050-32,339
Net finance costs -55,159-57,896-8,955
Profit before tax -379,997-500,220-158,123
Income tax expense -4,330-4,569
Profit for the year -384,327-504,789-158,123
Profit attributable to owners -270,562-493,686-158,123
Balance Sheet
Item 201720182019-03
Cash and cash equivalents 58,512958,990824,866
Trade and bills receivables 19,9006,8215,821
Inventories 24,66825,20341,869
Total current assets 232,8961,086,985996,126
Total current liabilities 1,211,650533,443570,125
Total equity -75,9901,802,5491,674,829
Equity attributable to owners -80,0741,802,5491,674,829
Interest-bearing borrowings 758,428528,018687,913
Cash Flow Statement
Item 201720182019-03
Net cash from operating activities -134,288-52,179-67,575
Net cash from investing activities -471,662-735,375-195,295
Net cash from financing activities 541,3801,679,105145,498
Net increase in cash -64,570891,551-117,372
Depreciation of PP&E 26,38942,30612,277
Amortisation of intangible assets 195662305
Purchase of PP&E -115,387-137,070-74,051
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 49.45
First Day OpenHK$ 47.45
First Day Change-0.30%
First Day Volume6118470.0
First Day Turnover295655000.0
Use of Proceeds
1、約1,238.5百萬港元(或所得款項凈額的40.0%)將用于撥付持續進行的核心產品的臨床試驗、監管備案及注冊; 2、約464.5百萬港元(或所得款項凈額的15.0%)將用于撥付持續進行的其他候選生物類似藥(包括HLX12、HLX11及HLX14)的臨床試驗、監管備案及注冊; 3、約1,083.7百萬港元(或所得款項凈額的35.0%)將用于撥付持續進行的生物創新藥的臨床試驗、監管備案及注冊以及開發免疫腫瘤聯合療法; 4、約309.6百萬港元(或所得款項凈額的10.0%)將分配至營運資金及一般企業用途。

Underwriting Syndicate

Joint Sponsors (5)
中国国际金融香港证券有限公司 CE AEN894 Merrill Lynch (Asia Pacific) Limited CE AAC198 招银国际融资有限公司 CE AVM940 Fosun International Securities Limited CE AAF432 Citigroup Global Markets Asia Limited CE AAA137
Overall Coordinators (7)
中国国际金融香港证券有限公司 CE AEN894 Merrill Lynch (Asia Pacific) Limited CE AAC198 中银国际亚洲有限公司 CE AET863 UBS Securities Hong Kong Limited CE BIN466 招银国际融资有限公司 CE AVM940 Fosun International Securities Limited CE AAF432 Citigroup Global Markets Asia Limited CE AAA137
Joint Bookrunners (15)
中国国际金融香港证券有限公司 CE AEN894 Merrill Lynch (Asia Pacific) Limited CE AAC198 中银国际亚洲有限公司 CE AET863 UBS Securities Hong Kong Limited CE BIN466 招银国际融资有限公司 CE AVM940 Fosun International Securities Limited CE AAF432 Citigroup Global Markets Asia Limited CE AAA137 海通国际证券有限公司 CE AAF806 oOo Securities (HK) Group Limited CE AJH488 BNP PARIBAS SECURITIES (ASIA) LIMITED CE AAF669 ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 农银国际融资有限公司 CE AWL249 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536 SBI China Capital Financial Services Limited CE ABD523
Joint Lead Managers (15)
中国国际金融香港证券有限公司 CE AEN894 Merrill Lynch (Asia Pacific) Limited CE AAC198 中银国际亚洲有限公司 CE AET863 UBS Securities Hong Kong Limited CE BIN466 招银国际融资有限公司 CE AVM940 Fosun International Securities Limited CE AAF432 Citigroup Global Markets Asia Limited CE AAA137 海通国际证券有限公司 CE AAF806 oOo Securities (HK) Group Limited CE AJH488 BNP PARIBAS SECURITIES (ASIA) LIMITED CE AAF669 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 农银国际证券有限公司 CE ACX411 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536 SBI China Capital Financial Services Limited CE ABD523

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Al-Rayyan Holding LLC 704,999,520 HKD — 21.97% — 6 months 2020-03-25
2 AVICT Global Holdings Limited 235,208,160 HKD — 7.33% — 6 months 2020-03-25
3 Henlius Biopharmaceuticals Inc. 78,402,720 HKD — 2.44% — 6 months 2020-03-25
4 浙江舒泰神投资有限公司 78,402,720 HKD — 2.44% — 6 months 2020-03-25

Directors & Management

PositionChinese nameEnglish Name
Chairman陳啟宇—
Company Secretary郭新軍、梁晶晶—
No director data available.

Major Shareholders

Major Shareholders & Holdings復星醫藥透過其全資附屬公司復星醫藥產業發展及復星新藥間接持有約53.76%已發行股份;最終控股股東為郭廣昌先生,其透過FIHL、FHL、復星國際、復星高科技等控制本公司。復星新藥直接持有內資股265,971,569股(佔49.33%)。
About this page

This page shows Henlius (02696) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect